Home / Stocks / Kopran Ltd
KOPRAN

Kopran Ltd Share Price

Live price, chart and which mutual funds hold this stock

…

as of —

₹—

Change

—

Day Open

₹—

Day High

₹—

Day Low

₹—

NSE Close — 19 Nov 2026

₹267.05

Change

+1.12 (0.42%)

Open

₹267.7

Prev. Close

₹265.93

Day High

₹272.1

Day Low

₹263.81

Volume Analysis

Traded

133,075

Delivered

56,358

Delivery %

42.35%

End-of-day NSE price via the official Bhavcopy — updated once daily after market close, not a live tick.

Strengths, Weaknesses, Opportunities & Threats

Strengths (0)

No signal for this stock

Weaknesses (2)

  • •Low return on equity (4.91%)
  • •Promoter holding is falling

Opportunities (0)

No signal for this stock

Threats (0)

No signal for this stock

Rule-based signals from the fundamentals below — not investment advice.

Pivot Levels

Type R3 R2 R1 Pivot S1 S2 S3
Classic ₹279.78 ₹275.94 ₹271.49 ₹267.65 ₹263.2 ₹259.36 ₹254.91
Fibonacci ₹275.94 ₹272.77 ₹270.82 ₹267.65 ₹264.48 ₹262.53 ₹259.36
Camarilla ₹269.33 ₹268.57 ₹267.81 ₹267.65 ₹266.29 ₹265.53 ₹264.77

Support/resistance levels for today, calculated from the previous trading day's high/low/close.

Absolute Returns

YTD

+76.22%

1 Week

-4.58%

1 Month

+1.14%

3 Months

+36.19%

6 Months

+63.65%

1 Year

+99.29%

2Y/3Y/5Y not shown yet — price history tracking only goes back to mid-2025 so far.

Stock Vitals

Computed from the latest available annual financials.

Graham Number

₹114.33

Current price is above the Graham Number — Benjamin Graham's estimate of fair value based on earnings and book value.

DuPont ROE Breakdown

6.38%

Net margin 4.91% × asset turnover 0.71x × equity multiplier 1.83x

Company Overview

Sector

Healthcare

Market Cap

₹1,281 Cr

P/E (TTM)

32.6

ROE

4.91%

Book Value

₹109.0

Face Value

₹10.0

Source: Screener.in (Consolidated figures) — data as of 18 Nov 2026. Not investment advice.

TopFund Analysis

Kopran Ltd lands in the middle of the pack on TopFund's composite fundamentals check within the Healthcare sector, at 51/100. The strongest factor is Financial Strength (95/100), while Growth (17/100) is the weakest area to weigh before deciding. Notably: Low return on equity (4.91%); promoter holding is falling.

TopFund Score — Fundamentals Quality

51/100 — Average

Data confidence: 80/100 (High Confidence) — based on how complete and how fresh the underlying data is.

As of 19 Nov 2026 · How we calculate this →

Financial Strength

95

Growth

17

Valuation

45

Cash Flow

35

Corporate Governance

71

Momentum

84

Institutional Ownership

30

Business Quality

42

Risk & Volatility

52

Liquidity

33

From Screener.in

  • +Company is expected to give good quarter
  • +Company has been maintaining a healthy dividend payout of 40.8%
  • −Promoter holding has decreased over last quarter: -2.60%
  • −The company has delivered a poor sales growth of 6.74% over past five years.
  • −Company has a low return on equity of 7.71% over last 3 years.
  • −Company might be capitalizing the interest cost

Not investment advice — an automated read of public fundamentals data, for research context only.

Corporate Actions

Kopran says no undisclosed material event caused the recent volume surge.

Exchange has sought clarification from Kopran Ltd on November 13, 2026, with reference to Movement in Volume.

Promoter Sarvamangal Mercantile bought 170,000 Kopran shares on Sept. 29, holding rose to 6.36%.

Newspaper Publication of Financial Result Q2 of FY 2026-27.

Investor Presentation on Q2 FY 2026-27 Results

Source: BSE regulatory filings, via Screener.in.

Quarterly Results

Last several quarters

  Sep 2023 Dec 2023 Mar 2024 Jun 2024 Sep 2024 Dec 2024 Mar 2025 Jun 2025 Sep 2025 Dec 2025 Mar 2026 Jun 2026 Sep 2026
Sales + 153 159 186 139 152 166 172 135 118 194 234 154 211
Expenses + 130 135 164 121 137 146 155 121 123 177 201 138 196
Operating Profit 23 24 22 18 15 20 17 14 -5 18 33 16 15
OPM % 14.96% 14.84% 11.66% 13.02% 9.72% 11.94% 9.92% 10.45% -4.48% 9.14% 14.08% 10.27% 7.29%
Other Income + 0 2 10 3 1 0 3 3 0 0 0 2 1
Interest 2 2 3 2 2 2 3 3 2 3 3 3 4
Depreciation 3 3 4 4 4 4 4 4 4 4 5 6 6
Profit before tax 18 21 25 15 10 14 14 10 -12 11 25 9 6
Tax % 24.55% 23.02% 26.01% 24.69% 23.42% 24.96% 29.39% 24.67% -14.63% 13.04% 25.57% 23.84% 25.47%
Net Profit + 14 16 19 11 7 10 10 7 -10 9 19 7 4
EPS in Rs 3 3 4 2 2 2 2 2 -2 2 4 1 1
Raw PDF — — — — — — — — — — — — —
YoY Sales growth 30 1 25 19 -1 5 -7 -3 -22 17 36 14 79

Source: Screener.in — figures in ₹ Crores unless marked %.

Profit & Loss (Yearly)

  Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026 TTM
Sales + 326 296 310 313 358 360 492 478 551 615 630 681 794
Expenses + 294 266 274 283 312 313 410 390 499 540 557 619 712
Operating Profit 31 30 36 31 46 47 82 87 52 74 73 62 82
OPM % 10.0% 10.0% 12.0% 10.0% 13.0% 13.0% 17.0% 18.0% 9.0% 12.0% 12.0% 9.0% 10.0%
Other Income + -48 1 11 9 3 0 18 11 3 15 4 0 3
Interest 13 13 14 9 9 9 6 5 6 9 9 10 13
Depreciation 10 8 8 9 9 10 10 11 13 13 16 17 21
Profit before tax -39 11 25 23 32 28 83 82 36 68 52 34 51
Tax % 0.0% 0.0% 20.0% 10.0% 24.0% 26.0% 26.0% 25.0% 24.0% 25.0% 26.0% 25.0% —
Net Profit + -39 11 20 20 24 21 62 61 27 51 39 26 39
EPS in Rs -10 2 5 5 6 5 14 13 6 11 8 5 8
Dividend Payout % 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 21.0% 24.0% 53.0% 28.0% 38.0% 56.0% —
Sales growth 8 -9 5 1 14 0 37 -3 15 12 2 8 34

Source: Screener.in — figures in ₹ Crores unless marked %.

Balance Sheet

  Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026 Sep 2026
Reserves 49 57 81 101 125 146 202 378 391 443 470 482 480
Borrowings + 86 80 95 89 97 88 66 75 75 99 148 153 208
Other Liabilities + 99 84 78 82 85 92 128 110 135 153 178 225 227
Total Liabilities 275 264 298 315 351 370 439 611 650 743 844 908 964
Fixed Assets + 102 101 104 104 113 111 112 151 165 182 208 346 378
CWIP 1 3 6 10 24 30 43 36 70 97 113 25 12
Investments 0 0 0 0 0 0 0 0 0 0 0 0 0
Other Assets + 172 160 187 201 214 229 284 425 415 465 522 537 574
Total Assets 275 264 298 315 351 370 439 611 650 743 844 908 964
Equity Capital 41 43 43 43 43 43 43 48 48 48 48 48 48

Source: Screener.in — figures in ₹ Crores unless marked %.

Cash Flow

  Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026
Cash from Operating Activity + 46 29 16 26 25 31 60 -33 34 43 42 67
Cash from Investing Activity + -10 -9 -18 -11 -25 -13 -25 -84 -13 -44 -56 -65
Cash from Financing Activity + -37 -19 2 -15 -1 -18 -35 123 -20 1 26 -21
Net Cash Flow 0 0 0 0 0 0 0 5 2 1 11 -19
Free Cash Flow 35 18 0 14 -6 17 43 -76 -27 -13 -17 0
CFO/EBITDA Share of operating profit converting into cash: CFO (before tax) / Operating Profit 147 95 47 94 63 82 93 -17 90 77 76 117

Source: Screener.in — figures in ₹ Crores unless marked %.

Shareholding Pattern

Quarter-by-quarter — Promoters, FII, DII & public holding trend

Promoter holding: 44.49% → 41.83%
  Dec 2023 Mar 2024 Jun 2024 Sep 2024 Dec 2024 Mar 2025 Jun 2025 Sep 2025 Dec 2025 Mar 2026 Jun 2026 Sep 2026
Public 54.88% 53.47% 54.68% 53.98% 54.68% 54.45% 54.81% 54.99% 55.21% 55.01% 55.06% 57.26%
Promoters 44.49% 44.49% 44.49% 44.49% 44.45% 44.42% 44.43% 44.43% 44.43% 44.43% 44.43% 41.83%
FII 0.48% 0.84% 0.68% 1.31% 0.86% 1.11% 0.76% 0.6% 0.36% 0.57% 0.51% 0.91%
DII 0.14% 1.2% 0.14% 0.22% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%

Source: Screener.in — quarterly shareholding disclosures.

Peers Comparison

Healthcare — ranked by market cap

Company Market Cap (Cr) P/E P/B ROE
Kopran Ltd (this stock) 1,281 32.6 2.44 4.91%
Gujarat Kidney N Sup Sp L 1,269 66.8 4.82 11.1%
Shalby Limited 1,340 34.2 1.31 2.45%
Anlon Healthcare Limited 1,348 37.8 5.25 18.4%
Fermenta Biotech Ltd. 1,367 29.4 3.27 17.3%
Jagsonpal Pharmaceuticals 1,402 — 5.82 —
3b Blackbio Dx Ltd. 1,157 19.7 3.33 19.8%

Which Mutual Funds Hold Kopran Ltd?

Frequently Asked Questions about Kopran Ltd

Community Sentiment

What are other investors saying about Kopran Ltd?

No votes yet — be the first to share your view.

Sign in to vote

Discussion

User-generated content — not investment advice, and not verified or endorsed by TopFund.

Sign in to join the discussion

No comments yet — start the discussion.